United Therapeutics (NASDAQ:UTHR) COO Sells $1,961,050.00 in Stock

Key Points

• Michael Benkowitz, COO of United Therapeutics, sold a total of $1,961,050 in company stock on September 8th, following previous sales of larger amounts in early September.
• United Therapeutics reported Q2 earnings that missed analyst expectations, with an EPS of $6.41 against a consensus of $6.80, while revenue was also slightly below estimates.
• Investment analysts are generally optimistic about United Therapeutics, with a consensus rating of "Moderate Buy" and an average price target of $438.85, following positive adjustments from multiple firms.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 5,000 shares of the firm's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $392.21, for a total value of $1,961,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The shares were sold at an average price of $397.41, for a total value of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00.

United Therapeutics Stock Performance

United Therapeutics stock traded down $7.30 during midday trading on Wednesday, reaching $396.50. The company's stock had a trading volume of 650,182 shares, compared to its average volume of 565,346. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The stock's 50 day simple moving average is $312.09 and its 200 day simple moving average is $306.29. The firm has a market capitalization of $17.89 billion, a PE ratio of 15.48, a P/E/G ratio of 6.02 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics's revenue was up 11.7% compared to the same quarter last year. During the same period last year, the business posted $5.85 EPS. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. F m Investments LLC increased its stake in shares of United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after acquiring an additional 33 shares during the last quarter. HB Wealth Management LLC grew its holdings in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock worth $355,000 after purchasing an additional 35 shares during the period. Hohimer Wealth Management LLC grew its holdings in shares of United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after purchasing an additional 37 shares during the period. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the period. Finally, Park Avenue Securities LLC grew its holdings in shares of United Therapeutics by 1.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company's stock worth $676,000 after purchasing an additional 39 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on UTHR shares. Bank of America lifted their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Oppenheimer lifted their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research note on Wednesday. Morgan Stanley cut their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $438.85.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.